» Articles » PMID: 38850443

Modulation of the Skin and Gut Microbiome by Psoriasis Treatment: a Comprehensive Systematic Review

Overview
Specialty Dermatology
Date 2024 Jun 8
PMID 38850443
Authors
Affiliations
Soon will be listed here.
Abstract

The microbiome is intricately linked to the development of psoriasis, serving as both a potential cause and consequence of the psoriatic process. In recent years, there has been growing interest among psoriasis researchers in exploring how psoriasis treatments affect the skin and gut microbiome. However, a comprehensive evaluation of the impact of modern treatment approaches on the microbiome has yet to be conducted. In this systematic review, we analyze studies investigating alterations in the skin and gut microbiome resulting from psoriasis treatment, aiming to understand how current therapies influence the role of the microbiome in psoriasis development. The systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. PubMed and Scopus databases were searched for eligible studies from the inception dates until July 5, 2023. Study selection, data extraction, and risk of bias assessment were carried out by three overlapping pairs of reviewers, resolving any disagreements through consensus. Our analysis of various treatments, including biologics, conventional medications, phototherapy, and probiotics, reveals significant shifts in microbial diversity and abundance. Importantly, favorable treatment outcomes are associated with microbiota alterations that approach those observed in healthy individuals. While the studies reviewed exhibit varying degrees of bias, underscoring the need for further research, this review supports the potential of microbiome modulation as both a preventive and therapeutic strategy for psoriasis patients. The findings underscore the importance of personalized therapeutic approaches, recognizing the profound impact of treatment on the microbiome. They also highlight the promise of probiotics, prebiotics, and dietary interventions in psoriasis management.

Citing Articles

The efficacy and safety of probiotics in the adjuvant treatment of psoriasis: a systematic review and meta-analysis of randomized controlled trials.

Zhu Y, Xu F, Chen H, Zheng Q Front Med (Lausanne). 2024; 11:1448626.

PMID: 39328313 PMC: 11426359. DOI: 10.3389/fmed.2024.1448626.

References
1.
Jankowiak B, Kowalewska B, Krajewska-Kulak E, Khvorik D . Stigmatization and Quality of Life in Patients with Psoriasis. Dermatol Ther (Heidelb). 2020; 10(2):285-296. PMC: 7090112. DOI: 10.1007/s13555-020-00363-1. View

2.
Reid C, Griffiths C . Psoriasis and Treatment: Past, Present and Future Aspects. Acta Derm Venereol. 2020; 100(3):adv00032. PMC: 9128930. DOI: 10.2340/00015555-3386. View

3.
Nast A, Smith C, Spuls P, Avila Valle G, Bata-Csorgo Z, Boonen H . EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020; 34(11):2461-2498. DOI: 10.1111/jdv.16915. View

4.
Mastorino L, Roccuzzo G, Dapavo P, Siliquini N, Avallone G, Rubatto M . Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult-to-treat population. Br J Dermatol. 2022; 187(2):263-265. PMC: 9545173. DOI: 10.1111/bjd.21048. View

5.
Ciazynska M, Olejniczak-Staruch I, Sobolewska-Sztychny D, Narbutt J, Skibinska M, Lesiak A . The Role of NLRP1, NLRP3, and AIM2 Inflammasomes in Psoriasis: Review. Int J Mol Sci. 2021; 22(11). PMC: 8198493. DOI: 10.3390/ijms22115898. View